COMPARATIVE ANALYSIS OF TOTAL MEDICAL EXPENDITURE OF THERAPY WITH NEBULIZED BUDESONIDE AND SYSTEMIC CORTICOSTEROIDS FOR PATIENTS WITH COPD EXACERBATION
Author(s)
Yao W1, You X2, Liu T2, Liu Y3, Huang H3
1Peking University Third Hospital, Beijing, China, 2AstraZeneca, Beijing, China, 3AstraZeneca, Shanghai, China
BACKGROUND: Almost all international guidelines recommend corticosteroids for management of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Previous research demonstrated that nebulized budesonide alone can be used as an alternative to systemic corticosteroids, while reducing the risk of occurrence of side effects in such patients. However, few studies examined the medical expenditure differences among two treatment groups in China. OBJECTIVES: This study compared the total medical expenditure of patients hospitalized with AECOPD treated with nebulized budesonide or systemic corticosteroids. METHODS: Data were pooled from 3,121 hospitalized AECOPD who had participated in a multicenter observational study (NCT02051166) from January to September 2014 in China. Patients received nebulized budesonide or systemic corticosteroids were included in the analysis; patients who died or with tracheal tube treatment or lung cancer were excludedgeneral multivariable linear regression model controlling for age, gender, comorbidity, and respiratory failure on admission. RESULTS: The per capita medical expenditure of patients receiving nebulized budesonide and systemic corticosteroids was 13,298 RMB and 13,987 RMB, respectively. The general linear model indicated that the patients with comorbidity (P<) and those suffering respiratory failure type II (P<) had significantly higher medical expenditure. However, the total medical expenditure of patients receiving nebulized budesonide was significantly lower than the systemic corticosteroids group (P=0.0007). CONCLUSIONS: Results from this post hoc analysis suggest that treatment with nebulized budesonide may yield important cost savings (per capita 1,259 RMB) for hospitalized AECOPD patients compared with treatment with systemic corticosteroids, on the basis of all necessary treatments.
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Value in Health, Vol. 21, S1 (May 2018)
Code
PRS35
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders